[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vestibular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vestibular-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,79,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100373459","human-visual-and-vestibular-motion-perception-study-100373459",false,"NCT04142697","Human Visual and Vestibular Motion Perception Study","Visual and Vestibular Percepts of Motion","Inclusion Criteria:\n\nHealthy subjects:\n\n* general good health\n\nVestibular Disease patients:\n\n* general good health\n* specific unilateral or bilateral vestibular loss\n\nExclusion Criteria:\n\nHealthy subjects:\n\n* subjects who are institutionalized or otherwise not self-sufficient.\n* enduring sequelae due to diseases of the nervous system, eyes, ears, head and neck, and limbs, except for changes commensurate with normal aging (e.g. presbyacusic hearing loss, mild cataract, etc.).\n* abnormal cognitive function, which if in question can be determined as a score of \\\u003C27 on the Mini-Mental State test.\n* corrected visual acuity worse than 20\u002F20 up to age 65, worse than 20\u002F40 if \\>65\n* abnormal binocular stereo-acuity or visual fields.\n* any defects in cranial nerve, oculomotor, cerebellar\u002Fcoordination, and somatosensory functions.\n* any abnormal oculomotor and vestibular function (caloric tests)\n\nVestibular Disease patients:\n\n* Inability to perform the study tasks due to sensory, motor, or postural limitations",true,"ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose this study is to measure sensitivity to visual and vestibular or balance motion. It is hoped that the results may help researchers better understand how aging and disease affect motion perception.",[28],"Vestibular Disease","RECRUITING","2026-01-08",{"date":32,"type":33},"2026-01-12","ACTUAL",{"date":35,"type":33},"2020-09-15",{"date":37,"type":22},"2027-09-01",{"name":39,"class":40},"University of Rochester","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100599076","telerehabilitation-decision-support-system-pilot-testing-protocol-100599076","NCT07079787","Telerehabilitation Decision Support System: Pilot Testing Protocol","Telerehabilitation of Balance Clinical and Economic Decision Support System","TeleRehab DSS","ALL PARTICIPANT Inclusion Criteria:\n\n* Age 40-80 years\n* community dwelling able to walk 500-m independently or with a stick\n* Depression subscale on Hospital Anxiety and Depression Scale \\\u003C10\u002F21 (14-item questionnaire)\n* No significant visual impairment (as self-reported by participants)\n* Willing to comply with study procedures, proposed training and testing regime\n* With capacity to consent\n* No acute musculoskeletal or other injuries that would prevent participation in a structured exercise program\n* Is not currently, and has not in the past 8-weeks received any falls\u002Fbalance\u002Fvestibular and\u002For cognitive rehabilitation.\n* Does not any implanted medical devices or a cardiac pacemaker.\n* Does not have any other co-existing neurological conditions (ie. Multiple sclerosis, Parkinson's disease, neuropathy etc.)\n* Does not have any language or communication deficits impairing their ability to communicate and\u002For express their thoughts.\n* Has at least one functional hand for grip function and computer use.\n* Fulfilling all of the criteria from one of the below sub-groups\n\nSTROKE COHORT who will fulfil the additional criteria:\n\n* Individuals with diagnosis of focal ischaemic or haemorrhagic stroke, as confirmed by a clinical letter.\n* Onset \\>\u002F= 3 months prior to study.\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* At risk of falls (i.e. Functional Gait Assessment FGA score \\\u003C\u002F=22\u002F30; FGA is a validated quick balance task assessment) AND\u002FOR having experienced a fall(s) in the last 12 months\n\nMCI COHORT who will fulfil the additional criteria:\n\n* Individuals with new or existing formal diagnosis of MCI, according to the International Classification of Disease 10 (ICD10) , as confirmed by a clinical letter.\n* At risk of falls (FGA \\\u003C\u002F= 22\u002F30) AND\u002FOR having experienced a fall(s) in the last 12 months.\n\nVESTIBULAR COHORT who will fulfill the additional criteria\n\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* Individuals with a diagnosis of a vestibular disorder (peripheral and\u002For mixed peripheral and central):\n* Peripheral vestibular disorder in which the balance problem lies in the vestibular\u002Fbalance system within the inner ear.\n* Mixed vestibular disorder in which the balance problem lies in the vestibular\u002Fbalance system within the inner ear (peripheral) and involving the nerves or neuronal network in the brain\u002Fbrainstem responsible for balance (central).\n* Chronic dizziness and\u002For unsteadiness (\\>\u002F= 3 months duration) that started at the time or after the vestibular disorder diagnosis.\n* Dizziness handicap inventory (DHI \\>34) AND\u002FOR At risk of falls (FGA \\\u003C\u002F=22\u002F30)\n\nLONG COVID-19 COHORT who will fulfill the additional criteria:\n\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* Individuals with laboratory confirmed diagnosis of Covid (\\>\u002F=6 months prior to study onset), as confirmed by a clinical letter.\n* Who have been diagnosed with long Covid, as confirmed by a clinical letter.\n* Who have chronic dizziness and\u002For unsteadiness which started after the Covid illness (self-report by the patient; duration \\\u003C\u002F=3 months).\n* Dizziness handicap inventory (DHI \\>34) AND\u002FOR At risk of falls (FGA \\\u003C\u002F=22\u002F30)\n\nExclusion Criteria:\n\n* Outside of the stated age bracket\n* Unable to walk independently (even with use of a walking stick)\n* MOCA score \\\u003C23\n* Score of 10 or higher on depression subscale of HADS\n* Unwilling to comply with study procedures, proposed training and testing regime\n* No capacity to consent\n* Significant visual impairment or homonymous hemianopia (stroke cohort only) (self-reported)\n* Orthostatic hypotension or uncontrolled hypertension\n* Other neurological problem (e.g. Parkingson's disease, Multiple Sclerosis etc.)\n* Language and communication deficits impairing ability to express thoughts (e.g. Aphasia)\n* Has participated in a clinical drug trial in the past 6 months.\n* Acute musculoskeletal injury that prevents participation in a structured exercise programme (e.g. lower limb fracture).\n* Has an implanted medical device or cardiac pacemaker.\n* Diagnosis of unstable Meniere's or with more than 4 migraines\u002Fmonth at the time of participating in the study\n* Not fulfilling the inclusion criteria for one of the sub-groups (such as criteria for Stroke group, or MCI group, or chronic vestibular disorder group, or long-Covid group), as outlined above.\n* Unable to provide a clinical letter confirming diagnosis.\n* For those with stroke, no visual spatial neglect.","40 Years",{"count":52,"type":22},30,[25],"This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. Further information is available at: https:\u002F\u002Fholobalance.eu\u002F. HOLOBalance was developed as a comprehensive rehabilitation protocol for individualised remote (tele)rehabilitation balance physiotherapy programme. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.\n\nThis pilot testing of a multisite randomised control trial (TeleRehab DSS, short for TeleRehabilitation Decision Support System) aims to investigating the usability and feasibility among a smaller sample population at each clinical site, identifying any technical bugs, and\u002For clinical procedural flaws to be remedied before delivery of the full-scale RCT.",[56,57,28,58],"Stroke","Mild Cognitive Impairment (MCI)","Long Covid-19",[60,61,62,63,64,65,66,67],"vestibular","rehabilitation","falls","balance","exercise","artificial intelligence","teleremedicine","physiotherapy","NOT_YET_RECRUITING","2025-07-18",{"date":71,"type":33},"2025-07-23",{"date":73,"type":22},"2025-07-25",{"date":75,"type":22},"2025-08-29",{"name":77,"class":40},"University College, London",5,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":41},"100587521","cisplatin-induced-cochlear-and-vestibular-damage-in-head-and-neck-cancer-100587521","NCT06929468","Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer","Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Squamous Cell Carcinoma: A Cohort Study","Inclusion Criteria:\n\n* Diagnosis of head and neck squamous cell carcinoma\n* Cisplatin-based chemoradiotherapy (monotherapy or combination-therapy, adjuvant or neo-adjuvant) or only radiotherapy (control group)\n* Age 18 to 85 years\n* Signed agreement and willingness to participate in the study and adhere to the study protocol\n\nExclusion Criteria:\n\n* Severe hearing impairment (WHO grade 3 or 4, corresponding to an audiometric ISO value of ≥61 dB in the better ear at frequencies of 500, 1000, 2000 and 4000 Hz)\n* Self-reported tinnitus or vestibular dysfunction in the last 3 months (only lead to exclusion of the corresponding secondary objectives, not to complete exclusion from the study)\n* Current cochlear implant\n* Concurrent treatment with loop diuretics (e.g. furosemide), aminoglycoside antibiotics or other known ototoxic substances in the last three months\n* Acute psychosis or serious psychiatric illness\n* Addiction disorder","85 Years",{"count":88,"type":22},55,"6 Months","OBSERVATIONAL","The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.",[93,94,95,96,97,98,99,28,100,101,102],"Ototoxic Hearing Loss","Ototoxicity, Drug-Induced","Cisplatin-induced Hearing Loss","Cisplatin Ototoxicity","Head and Neck Cancer","Dizzyness","Inner Ear Hearing Loss","Squamous Cell Carcinoma of the Head and Neck","Deafness","Hearing Loss","2025-04-14",{"date":105,"type":33},"2025-04-16",{"date":107,"type":22},"2025-07",{"date":109,"type":22},"2027-06",{"name":111,"class":40},"Simon Jäger",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100568606","effectiveness-of-vestaid-app-100568606","NCT06683417","Effectiveness of VestAid App","Vestibular Rehabilitation Aid (VestAid)","Inclusion:\n\n* Snellen visual acuity (corrected) greater than 20\u002F40\n* No more than 25dB hearing loss at 500,1000, 2000, and 4000 Hz\n* Ability to detect 4.31 using Semmes-Weinstein monofilament at the lower extremity\n* At least 40 degrees of neck yaw motion with only mild to moderate pain (6 or under on 0-10 numeric pain scale)\n* Internet access at home\n* No significant residual from past musculoskeletal or neuromuscular conditions\n* Ability ambulates unassisted\n* Diagnosed with a concussion or inner ear problem the last 30 days\n* Between 18-60 years of age\n* Can read and understand English\n* Has complaints of dizziness\n\nExclusion criteria:\n\n* Greater then 30 days since diagnosis of concussion\u002FmTBI or inner ear problem\n* No access to internet at home\n* Younger than 18 years of age or older than 60 years of age\n* Cannot read or understand English\n* No complaints of dizziness and\u002For balance deficits\n* Have significant neuropathy\n* Cannot see tablet clearly at 1 meter\n* Neck pain \\>5 on a 10-point pain scale.","60 Years",{"count":121,"type":22},80,[25],"This multi-center randomized trial (MCRT) will investigate the effectiveness of the VestAid application to provide equivalent or faster recovery from dizziness compared to standard-of-care delivery of vestibular rehabilitation exercises.",[125,28,126,127,128],"MTBI - Mild Traumatic Brain Injury","Balance Deficits","Vestibular Disorders","Dizziness",[130,131,132,133,134,135,136,137,138,139],"mTBI","vestibular rehabilitation","vestibular disorder","technology","application","dizziness","balance disorder","image processing","eye gaze compliance","VOR","2024-11-08",{"date":142,"type":33},"2024-11-12",{"date":144,"type":22},"2025-01-15",{"date":146,"type":22},"2025-12-30",{"name":148,"class":149},"BlueHalo","INDUSTRY"]